Clinical Trial Results:
Influence of a bolus administration of ephedrine and phenylephrine on spinal oxygen saturation, measured with NIRS.
Summary
|
|
EudraCT number |
2016-001839-13 |
Trial protocol |
BE |
Global end of trial date |
09 Sep 2017
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
15 Feb 2020
|
First version publication date |
15 Feb 2020
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
AGO/2016/006
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT03767296 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Ghent University Hospital
|
||
Sponsor organisation address |
Corneel Heymanslaan 10, Ghent, Belgium,
|
||
Public contact |
Bimetra Clinics, Ghent University Hospital, +32 93320500, bimetra.clinics@uzgent.be
|
||
Scientific contact |
Bimetra Clinics, Ghent University Hospital, +32 93320500, bimetra.clinics@uzgent.be
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
07 Dec 2018
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
09 Sep 2017
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
09 Sep 2017
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
Evaluation of the effect of vasoactive agents (ephedrine and phenylephrine) on the spinal vasculature by measuring spinal oxygenation, using near infrared spectroscopy in peripheral vascular surgery.
|
||
Protection of trial subjects |
Ethics review and approval, informed consent and routine monitoring.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
06 Feb 2017
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Belgium: 28
|
||
Worldwide total number of subjects |
28
|
||
EEA total number of subjects |
28
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
11
|
||
From 65 to 84 years |
15
|
||
85 years and over |
2
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
33 patients were included in the period 06-Feb-2017 until 09-Sep-2017. 5 drop-outs been replaced. End of trial notification was dated 09-Sep-2017 (last patient last visit) and submitted to EC and CA 06-Dec-2018. | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
Patients who are 18 years or older and who are scheduled for dilatation of arterial bloos vessels of the lower limb. Patients were screened as per inclusion and exclusion criteria per protocol. | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
overall trial (overall period)
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Not blinded | |||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Group 1 | |||||||||||||||
Arm description |
Ephedrine- Phenylephrine - Ephedrine | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Ephedrine
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for injection/infusion in pre-filled syringe
|
|||||||||||||||
Routes of administration |
Intravenous bolus use
|
|||||||||||||||
Dosage and administration details |
MAP decrease > 20%:
6 mg, 6mg, 9 mg, 9 mg, 12 mg, …..(max 24mg/bolus) (until x mg)
A total amount of 140 mg Ephedrine will not be exceeded.
|
|||||||||||||||
Investigational medicinal product name |
Phenylephrine
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for injection/infusion
|
|||||||||||||||
Routes of administration |
Intravenous bolus use
|
|||||||||||||||
Dosage and administration details |
MAP decrease >20%:
50μg, 50μg, 100μg, 100μg, 150μg, 150μg,…(max 500µg/bolus)
A total amount of 1500 μg will not be exceeded.
|
|||||||||||||||
Investigational medicinal product name |
Ephedrine
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for injection in pre-filled syringe
|
|||||||||||||||
Routes of administration |
Intravenous bolus use
|
|||||||||||||||
Dosage and administration details |
Decrease MAP > 20%:
6 mg, 6mg, 9 mg, 9 mg, 12 mg, …..(max 24mg/bolus) (starting from x mg)
A total amount of 140 mg Ephedrine will not be exceeded.
|
|||||||||||||||
Arm title
|
Group 2 | |||||||||||||||
Arm description |
Phenylephrine- Ephedrine - Phenylephrine | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Phenylephrine
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
|||||||||||||||
Routes of administration |
Intravenous bolus use
|
|||||||||||||||
Dosage and administration details |
MAP decrease > 20%:
50μg, 50μg, 100μg, 100μg, 150μg, 150μg,…(max 500µg/bolus) (until x mg)
A total amount of 1500 μg will not be exceeded.
|
|||||||||||||||
Investigational medicinal product name |
Ephedrine
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for injection in pre-filled syringe
|
|||||||||||||||
Routes of administration |
Intravenous bolus use
|
|||||||||||||||
Dosage and administration details |
Decrease MAP > 20%:
6 mg, 6mg, 9 mg, 9 mg, 12 mg, …..(max 24mg/bolus) (starting from x mg)
A total amount of 140 mg Ephedrine will not be exceeded.
|
|||||||||||||||
Investigational medicinal product name |
Phenylephrine
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
|||||||||||||||
Routes of administration |
Intravenous bolus use
|
|||||||||||||||
Dosage and administration details |
MAP decrease > 20%:
50μg, 50μg, 100μg, 100μg, 150μg, 150μg,…(max 500µg/bolus) (starting from x mg)
A total amount of 1500 μg will not be exceeded.
|
|||||||||||||||
Arm title
|
Group 3 | |||||||||||||||
Arm description |
Ephedrine- Ephedrine - Ephedrine | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Ephedrine
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for injection/infusion in pre-filled syringe
|
|||||||||||||||
Routes of administration |
Intravenous bolus use
|
|||||||||||||||
Dosage and administration details |
MAP decrease > 20%:
6 mg, 6mg, 9 mg, 9 mg, 12 mg, …..(max 24mg/bolus) (until x mg)
A total amount of 140 mg Ephedrine will not be exceeded.
|
|||||||||||||||
Investigational medicinal product name |
Ephedrine
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for injection/infusion in pre-filled syringe
|
|||||||||||||||
Routes of administration |
Intravenous bolus use
|
|||||||||||||||
Dosage and administration details |
MAP decrease > 20%:
6 mg, 6mg, 9 mg, 9 mg, 12 mg, …..(max 24mg/bolus) (from x mg until y mg)
A total amount of 140 mg Ephedrine will not be exceeded.
|
|||||||||||||||
Investigational medicinal product name |
Ephedrine
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for injection/infusion in pre-filled syringe
|
|||||||||||||||
Routes of administration |
Intravenous bolus use
|
|||||||||||||||
Dosage and administration details |
MAP decrease > 20%:
6 mg, 6mg, 9 mg, 9 mg, 12 mg, …..(max 24mg/bolus) (from y mg)
A total amount of 140 mg Ephedrine will not be exceeded.
|
|||||||||||||||
Arm title
|
Group 4 | |||||||||||||||
Arm description |
Phenylephrine- Phenylephrine - Phenylephrine | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Phenylephrine
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for injection/infusion
|
|||||||||||||||
Routes of administration |
Intravenous bolus use
|
|||||||||||||||
Dosage and administration details |
MAP decrease >20%:
50μg, 50μg, 100μg, 100μg, 150μg, 150μg,…(max 500µg/bolus) (until x mg)
A total amount of 1500 μg will not be exceeded.
|
|||||||||||||||
Investigational medicinal product name |
Phenylephrine
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for injection/infusion
|
|||||||||||||||
Routes of administration |
Intravenous bolus use
|
|||||||||||||||
Dosage and administration details |
MAP decrease >20%:
50μg, 50μg, 100μg, 100μg, 150μg, 150μg,…(max 500µg/bolus) (starting from x until y mg)
A total amount of 1500 μg will not be exceeded.
|
|||||||||||||||
Investigational medicinal product name |
Phenylephrine
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Solution for injection/infusion
|
|||||||||||||||
Routes of administration |
Intravenous bolus use
|
|||||||||||||||
Dosage and administration details |
MAP decrease >20%:
50μg, 50μg, 100μg, 100μg, 150μg, 150μg,…(max 500µg/bolus) (starting from y mg)
A total amount of 1500 μg will not be exceeded.
|
|||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group 1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Ephedrine- Phenylephrine - Ephedrine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group 2
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Phenylephrine- Ephedrine - Phenylephrine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group 3
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Ephedrine- Ephedrine - Ephedrine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group 4
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Phenylephrine- Phenylephrine - Phenylephrine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Group 1
|
||
Reporting group description |
Ephedrine- Phenylephrine - Ephedrine | ||
Reporting group title |
Group 2
|
||
Reporting group description |
Phenylephrine- Ephedrine - Phenylephrine | ||
Reporting group title |
Group 3
|
||
Reporting group description |
Ephedrine- Ephedrine - Ephedrine | ||
Reporting group title |
Group 4
|
||
Reporting group description |
Phenylephrine- Phenylephrine - Phenylephrine | ||
Subject analysis set title |
Ephedrine
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Patients treated with ephedrine for MAP decrease > 20%
|
||
Subject analysis set title |
Phenylephedrine
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Patients treated with phenylephedrine for MAP decrease > 20%
|
|
||||||||||||||||||||||
End point title |
Spinal oxygen saturation measured by NIRS (T3-T4) | |||||||||||||||||||||
End point description |
||||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||
End point timeframe |
From start induction until end of procedure
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Statistical analysis title |
Analysis | |||||||||||||||||||||
Comparison groups |
Ephedrine v Phenylephedrine
|
|||||||||||||||||||||
Number of subjects included in analysis |
42
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
equivalence | |||||||||||||||||||||
P-value |
< 0.001 | |||||||||||||||||||||
Method |
t-test, 2-sided | |||||||||||||||||||||
Parameter type |
Mean difference (final values) | |||||||||||||||||||||
Point estimate |
-2
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
-2.8 | |||||||||||||||||||||
upper limit |
-1.1 | |||||||||||||||||||||
Variability estimate |
Standard deviation
|
|
||||||||||||||||||||||
End point title |
Spinal oxygen saturation measured by NIRS (T9-T10) | |||||||||||||||||||||
End point description |
||||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||
End point timeframe |
From start induction until end of procedure
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Statistical analysis title |
Statystical analysis | |||||||||||||||||||||
Comparison groups |
Phenylephedrine v Ephedrine
|
|||||||||||||||||||||
Number of subjects included in analysis |
42
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
equivalence | |||||||||||||||||||||
P-value |
= 0.006 | |||||||||||||||||||||
Method |
t-test, 2-sided | |||||||||||||||||||||
Parameter type |
Mean difference (final values) | |||||||||||||||||||||
Point estimate |
-1.4
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
-2.4 | |||||||||||||||||||||
upper limit |
-0.4 | |||||||||||||||||||||
Variability estimate |
Standard deviation
|
|
||||||||||||||||||||||
End point title |
Spinal oxygen saturation measured by NIRS (L1-L2) | |||||||||||||||||||||
End point description |
||||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||
End point timeframe |
From start induction until end of procedure
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Statistical analysis title |
Statistical analysis | |||||||||||||||||||||
Comparison groups |
Ephedrine v Phenylephedrine
|
|||||||||||||||||||||
Number of subjects included in analysis |
42
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
equivalence | |||||||||||||||||||||
P-value |
< 0.001 | |||||||||||||||||||||
Method |
t-test, 2-sided | |||||||||||||||||||||
Parameter type |
Mean difference (final values) | |||||||||||||||||||||
Point estimate |
-1.5
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
-2.3 | |||||||||||||||||||||
upper limit |
-0.8 | |||||||||||||||||||||
Variability estimate |
Standard deviation
|
|
||||||||||||||||||||||
End point title |
Cerebral oxygenation (NIRS) | |||||||||||||||||||||
End point description |
||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
From start induction until end procedure
|
|||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Heartrate | |||||||||||||||||||||
End point description |
||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
From start induction until end procedure
|
|||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Blood pressure | |||||||||||||||||||||
End point description |
||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
From start induction until end procedure
|
|||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Total amount of vasoactive medication used | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From start induction until end of procedure
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
Adverse events information [1]
|
|||||||||||||||||||||||
Timeframe for reporting adverse events |
Adverse events will be reported between the first dose administration of trial medication and the last trial related activity.
|
||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||
Dictionary version |
21.1
|
||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||
Reporting group title |
Group 4
|
||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: No other adverse events occurred during the study |
|||||||||||||||||||||||
|
|||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
04 Oct 2016 |
Protocol update to version 6 |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |